SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)
Website: www.sinobiopharm.com
(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT
TQH3906 "TYK2/JAK1 JH2 ALLOSTERIC INHIBITOR" ACHIEVING POSITIVE PROGRESS IN THE PHASE II CLINICAL TRIAL FOR PLAQUE PSORIASIS

The board of directors (the "**Board**") of Sino Biopharmaceutical Limited (the "**Company**", together with its subsidiaries, the "**Group**") announces that TQH3906 "TYK2/JAK1 JH2 Allosteric Inhibitor", a Category 1 innovative drug independently developed by the Group, has recently completed its Phase II clinical trial for moderate-to-severe plaque psoriasis (PsO). The results showed that TQH3906 demonstrated good safety and tolerability across all dose groups and met the primary endpoint of the Phase II study.

This randomized, double-blind, placebo-controlled and multicenter Phase II study (NCT06542614) aims to evaluate the efficacy and safety of TQH3906 in subjects with moderate-to-severe plaque psoriasis. The study ultimately enrolled 209 patients, divided into a placebo group and five distinct TQH3906 dose groups, with doses administered orally once daily.

In terms of efficacy, TQH3906 demonstrated a favorable dose-response relationship and reached a pharmacodynamic plateau for the primary endpoint. At the anticipated recommended Phase II dose (RP2D), after 12 weeks of treatment, the PASI 75 (≥75% improvement in Psoriasis Area and Severity Index from baseline) response rate exceeded 90% and the PASI 90 (≥90% improvement) response rate exceeded 70%, significantly outperforming the placebo group (approximately 10% and 5%, respectively). Its efficacy profile is comparable to IL-17/IL-23 targeted biologics and superior to other marketed oral drugs for psoriasis (e.g., deucravacitinib and apremilast). Detailed data from this study will be presented at upcoming international academic conferences.

In terms of safety, TQH3906 demonstrated an overall favorable safety profile. The incidence of adverse events was comparable to the placebo group, with the vast majority of treatment emergent adverse events (TEAEs) being at Grade 1 or 2 in severity. Its safety characteristics were consistent with those of other TYK2 inhibitors, and no new safety signals identified.

Compared to antibody-based biologics, oral small-molecule targeted drugs offer advantages such as convenient administration, better tolerability, and improved patient compliance. Currently, the only approved oral small-molecule drugs for plaque psoriasis in China are PDE-4 inhibitors (apremilast and mufemilast) and deucravacitinib (TYK2 JH2 allosteric inhibitor). However, existing research data indicate that these drugs achieve only approximately 60% PASI 75 response rates and 40% PASI 90 response rates at 16 weeks of treatment, demonstrating significant efficacy gaps compared to biologics. This suggests an urgent clinical need for oral small-molecule drugs with better efficacy and controllable safety.

TQH3906 significantly enhances selectivity for JAK2, JAK3, and other kinases by targeting the pseudo-kinase domain (JH2) of TYK2/JAK1. Compared to traditional JAK inhibitors acting on the kinase domain (JH1), TQH3906 offers higher selectivity and potentially superior safety. Besides plaque psoriasis, the Group will continue investigating TQH3906 for multiple new indications in autoimmune and dermatological fields, including inflammatory bowel disease and psoriatic arthritis.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 29 December 2025

As at the date of this announcement, the Board of the Company comprises six executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, and Mr. Tian Zhoushan, and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.